2.70
price down icon12.34%   -0.38
after-market アフターアワーズ: 2.76 0.06 +2.22%
loading
前日終値:
$3.08
開ける:
$3
24時間の取引高:
247.29K
Relative Volume:
1.16
時価総額:
$104.65M
収益:
-
当期純損益:
$-27.66M
株価収益率:
-2.8421
EPS:
-0.95
ネットキャッシュフロー:
$-24.36M
1週間 パフォーマンス:
-30.59%
1か月 パフォーマンス:
-35.41%
6か月 パフォーマンス:
+13.92%
1年 パフォーマンス:
-58.01%
1日の値動き範囲:
Value
$2.70
$3.145
1週間の範囲:
Value
$2.70
$3.59
52週間の値動き範囲:
Value
$1.60
$6.50

Genelux Corp Stock (GNLX) Company Profile

Name
名前
Genelux Corp
Name
セクター
Healthcare (1164)
Name
電話
805-267-9889
Name
住所
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
GNLX's Discussions on Twitter

GNLX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
GNLX
Genelux Corp
2.70 104.65M 0 -27.66M -24.36M -0.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.82 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
634.23 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
591.87 36.10B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
270.02 35.03B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
272.17 28.24B 3.81B -644.79M -669.77M -6.24

Genelux Corp Stock (GNLX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-29 開始されました Guggenheim Buy
2024-08-28 開始されました ROTH MKM Buy
2023-11-27 開始されました H.C. Wainwright Buy
2023-09-12 開始されました Maxim Group Buy
2023-02-15 開始されました The Benchmark Company Speculative Buy

Genelux Corp (GNLX) 最新ニュース

pulisher
04:44 AM

Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements - TipRanks

04:44 AM
pulisher
07:38 AM

H.C. Wainwright maintains Buy on Genelux shares, target at $30 - Investing.com India

07:38 AM
pulisher
Mar 28, 2025

Genelux reports FY24 EPS (95c), consensus (88c) - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

FDA Green Light: Genelux's Cancer Drug Olvi-Vec Advances as 2024 Data Shows 71% Disease Control - Stock Titan

Mar 28, 2025
pulisher
Mar 28, 2025

GENELUX Corp SEC 10-K Report - TradingView

Mar 28, 2025
pulisher
Mar 28, 2025

Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

Genelux (GNLX) Projected to Post Quarterly Earnings on Friday - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp. - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

What is HC Wainwright’s Estimate for Genelux Q1 Earnings? - Defense World

Mar 27, 2025
pulisher
Mar 26, 2025

Benchmark maintains $25 target on Genelux following trial data - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Genelux’s (GNLX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Mar 26, 2025
pulisher
Mar 26, 2025

Genelux stock holds Buy rating, $30 target from H.C. Wainwright - Investing.com India

Mar 26, 2025
pulisher
Mar 25, 2025

Genelux prices 3M shares at $3.50 in underwritten public offering - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux announces alignment with FDA of approval pathway for Olvi-Vec - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux Announces FDA Guidance on Olvi-Vec Phase 3 Trial - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux Prices 3 Mln Stock Offering At $3.50/shr, Stock Fell - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux's Olvi-Vec Shows Anti-Tumor Effect in Phase 1b/2 Lung Cancer Study - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock - Yahoo Finance

Mar 25, 2025
pulisher
Mar 25, 2025

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease - Yahoo Finance

Mar 25, 2025
pulisher
Mar 02, 2025

Why Genelux Corporation (GNLX) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 02, 2025
pulisher
Mar 01, 2025

Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025 - Insider Monkey

Mar 01, 2025
pulisher
Feb 28, 2025

D.A. Davidson & CO. Makes New $51,000 Investment in Genelux Co. (NASDAQ:GNLX) - Defense World

Feb 28, 2025
pulisher
Feb 16, 2025

Apollon Wealth Management LLC Grows Stock Holdings in Genelux Co. (NASDAQ:GNLX) - Defense World

Feb 16, 2025
pulisher
Feb 13, 2025

Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - simplywall.st

Feb 13, 2025
pulisher
Feb 08, 2025

Genelux Corporation (NASDAQ:GNLX) Announces CFO Transition and Appointment of New CFOGenelux Corporation, a leading biotechnology company, recently disclosed in an SEC filing that Lourie Zak has resigned as Chief Financial Officer, effective imm - Defense World

Feb 08, 2025
pulisher
Feb 07, 2025

Genelux Corporation Announces Matt Pulisic Serves as Principal Financial Officer and Principal Accounting Officer - Marketscreener.com

Feb 07, 2025
pulisher
Feb 05, 2025

Genelux appoints new CFO as Lourie Zak departs - MSN

Feb 05, 2025
pulisher
Feb 03, 2025

Genelux Corporation Announces New Chief Financial Officer - Markets Insider

Feb 03, 2025
pulisher
Feb 03, 2025

Genelux appoints new CFO amid clinical advancements - Investing.com

Feb 03, 2025
pulisher
Feb 03, 2025

Genelux Corp. Appoints New CFO Amid Leadership Change - TipRanks

Feb 03, 2025
pulisher
Jan 28, 2025

Oncolytic Viruses Market Expected to rise, 2034 | Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen - Barchart

Jan 28, 2025
pulisher
Jan 24, 2025

Genelux (GNLX) Stock Price, News & Analysis - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Yahoo Finance

Jan 24, 2025
pulisher
Jan 23, 2025

Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers? - RTTNews

Jan 23, 2025
pulisher
Jan 12, 2025

Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World

Jan 12, 2025
pulisher
Dec 31, 2024

Genelux director Tyree James L sells shares worth $8,511 - Investing.com India

Dec 31, 2024
pulisher
Dec 30, 2024

Genelux director Tyree James L sells shares worth $8,511 By Investing.com - Investing.com Nigeria

Dec 30, 2024
pulisher
Dec 23, 2024

XTX Topco Ltd Invests $59,000 in Genelux Co. (NASDAQ:GNLX) - Defense World

Dec 23, 2024
pulisher
Dec 19, 2024

Genelux VP sells shares worth $14,742 By Investing.com - Investing.com Australia

Dec 19, 2024
pulisher
Dec 18, 2024

Genelux CFO Zak Lourie sells $4,921 in stock By Investing.com - Investing.com Australia

Dec 18, 2024
pulisher
Dec 18, 2024

Genelux's head of regulatory sells $5,873 in stock By Investing.com - Investing.com Australia

Dec 18, 2024
pulisher
Dec 18, 2024

Genelux CFO Zak Lourie sells $4,921 in stock - Investing.com

Dec 18, 2024
pulisher
Dec 18, 2024

Genelux CEO Zindrick Thomas sells $33,497 in stock - Investing.com

Dec 18, 2024
pulisher
Dec 13, 2024

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - Yahoo Finance

Dec 13, 2024
pulisher
Nov 19, 2024

HC Wainwright Cuts Genelux (NASDAQ:GNLX) Price Target to $30.00 - Defense World

Nov 19, 2024
pulisher
Nov 15, 2024

Genelux shares target cut, maintains buy rating on 3Q earnings - Investing.com

Nov 15, 2024
pulisher
Nov 14, 2024

Genelux reports Q3 EPS (19c), consensus (19c) - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates - Yahoo Finance

Nov 14, 2024
pulisher
Nov 08, 2024

Genelux Corp. Releases New Corporate Presentation - TipRanks

Nov 08, 2024

Genelux Corp (GNLX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$70.69
price down icon 1.05%
$76.29
price down icon 2.18%
$31.13
price down icon 0.77%
$19.29
price down icon 5.07%
$91.06
price down icon 4.10%
biotechnology ONC
$272.17
price up icon 1.79%
大文字化:     |  ボリューム (24 時間):